Form 8-K - Current report:
SEC Accession No. 0001193125-26-294613
Filing Date
2026-07-02
Accepted
2026-07-02 16:20:52
Documents
14
Period of Report
2026-06-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K pyxs-20260630.htm   iXBRL 8-K 66857
2 EX-4.1 pyxs-ex4_1.htm EX-4.1 163155
3 EX-10.1 pyxs-ex10_1.htm EX-10.1 481880
4 EX-10.2 pyxs-ex10_2.htm EX-10.2 220229
5 EX-99.1 pyxs-ex99_1.htm EX-99.1 32039
6 GRAPHIC img244827169_0.jpg GRAPHIC 46807
  Complete submission text file 0001193125-26-294613.txt   1267736

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT pyxs-20260630.xsd EX-101.SCH 25999
17 EXTRACTED XBRL INSTANCE DOCUMENT pyxs-20260630_htm.xml XML 4914
Mailing Address 321 HARRISON AVENUE BOSTON MA 02118
Business Address 321 HARRISON AVENUE BOSTON MA 02118 (617) 221-9059
Pyxis Oncology, Inc. (Filer) CIK: 0001782223 (see all company filings)

EIN.: 831160910 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40881 | Film No.: 261151601
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)